Stocks To Buy: GSK Pharma, Apcotex Industries are top picks for big gains, says Vikas Sethi in chat with Anil Singhvi

Stocks To Buy: Amid quarterly result announcements season, index specific trade pattern has gone backstage as traders have started to maintain stock specific trade. Zee Business Managing Editor Anil Singhvi has been repeatedly asking stock market investors to follow stocks in this manner. In this regard the Market Guru today asked Vikas Sethi, Managing Director at Sethi Finmart to share his top picks of the day and he responded with GSK Pharma and Apcotex Industries as shares to buy for whopping gains.

Speaking on the GSK Pharma shares Sethi, said, "My first short-term pick is GSK Pharma which is also called GlaxoSmitKline Pharmacuticals. UK-based Glaxo Pharma develops 30 vaccines which is exported in near 160 countries. If any company in the world succeeds in developing Coronavirus Vaccine, then GSK Pharma will have a role to play in the marketing of COVID-19 vaccine. Apart from this, the company has strong fundamentals as its ROE is at 20 per cent and ROC stands at 26 per cent. It's a zero debt company with DIIs holding near 14 per cent shares while promoters hold 75 per cent of GSK Pharma shares."

See Zee Business Live TV streaming below:

Sethi recommended stock market traders to buy GSK Pharma shares at current market price of Rs 1,535 for the target of Rs 1,625. However, he strictly advised to maintain the stop loss at Rs 1,440 per stock levels.

Watch full coverage in video below:

शॉर्ट टर्म में ज्यादा मुनाफा....जानिए सदाबहार सेठी सा'ब ने किस शेयर में दी खरीदारी करने की सलाह?@AnilSinghvi_ @vikassethi_SF pic.twitter.com/fOEh7sl4lW

— Zee Business (@ZeeBusiness) August 13, 2020

On his second pick of the day Sethi told Anil Singhvi, "My second pick is Apcotex Industries that develops synthetic rubber, which is used in making Coronavirus gloves. Company's fundamentals are very strong as its Debt Equity Ratio is at 0.17 per cent while three years CAGR profit is at near 15 per cent. I would advise investors to buy the counter at current levels of Rs 137 for immediate short-term target of Rs 150."